Physician profile
Howard Min
NPI 1972585859
$10,583.08
in general payments reported to CMS, 2019-2025
47 companies · $1,878 in 2025
The $1,878 reported for 2025 was more than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,879 · 2020: $1,412 · 2021: $1,483 · 2022: $765 · 2023: $1,494 · 2024: $1,672 · 2025: $1,878.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,044.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,044.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $1,829.11 | 2019-2025 | Lifevest |
| Abbott Laboratories | $839.57 | 2019-2025 | Cardiomems, Jot Dx, Assurity |
| Kowa Pharmaceuticals America, INC. | $815.04 | 2020-2022 | |
| Novartis Pharmaceuticals Corporation | $698.98 | 2019-2025 | |
| Amgen INC. | $692.63 | 2019-2025 | Repatha, Repatha |
| Amarin Pharma, INC. | $688.17 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $629.38 | 2019-2024 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $484.12 | 2019-2025 | Camzyos, Eliquis |
| Esperion Therapeutics, INC. | $465.40 | 2023-2025 | Nexletol |
| Astrazeneca Pharmaceuticals Lp | $421.87 | 2019-2025 | Wainua, Farxiga |
| Pfizer INC. | $305.25 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $230.67 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $222.24 | 2019-2024 | |
| Kiniksa Pharmaceuticals International, Plc | $195.26 | 2024 | Arcalyst |
| Boston Scientific Corporation | $189.06 | 2019-2025 | Watchman Flx, Lux-Dx Insertable Cardiac Monitor |
Show all 47 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abiomed | $149.64 | 2019-2025 | Impella |
| Novo Nordisk INC | $144.98 | 2023-2024 | Ozempic, Rybelsus |
| Merck Sharp & Dohme LLC | $135.70 | 2023-2025 | Verquvo, Winrevair |
| Baxter Healthcare | $106.53 | 2025 | Hillrom - Carnation Ambulatory Monitor, Hillrom - Cardiac Ambulatory Monitor |
| Cathworks, INC. | $105.09 | 2019-2022 | |
| Impulse Dynamics (USA) INC. | $94.39 | 2022-2023 | Optimizer |
| Atricure, INC. | $91.33 | 2022-2025 | Atriclip Laa Exclusion System |
| Biotronik INC. | $87.64 | 2019-2025 | Amvia Edge |
| Akcea Therapeutics, INC. | $74.81 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $74.34 | 2025 | |
| Heartflow, INC. | $71.86 | 2024-2025 | |
| Lexicon Pharmaceuticals, INC. | $63.71 | 2024 | |
| Alnylam Pharmaceuticals INC. | $62.81 | 2024-2025 | Amvuttra |
| Cvrx, INC. | $60.75 | 2025 | Barostim Neo System |
| Irhythm Technologies, INC. | $60.41 | 2019-2023 | Zio Xt Patch |
| Regeneron Healthcare Solutions, INC. | $53.78 | 2019 | |
| Kiniksa Pharmaceuticals, Ltd. | $51.08 | 2023 | Arcalyst |
| Philips North America LLC | $45.74 | 2024-2025 | Mcot, (5044) Mcot |
| Astellas Pharma US INC | $39.54 | 2019-2020 | |
| Bridgebio Pharma, INC. | $37.08 | 2025 | Attruby |
| Kestra Medical Technology Services, INC. | $34.10 | 2024 | Assure Wcd |
| Glaxosmithkline, LLC. | $32.94 | 2025 | Shingrix |
| Ionis Pharmaceuticals, INC. | $32.41 | 2025 | Tryngolza |
| Gilead Sciences, INC. | $25.16 | 2019 | |
| Shockwave Medical, INC | $25.02 | 2023 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Terumo Medical Corporation | $23.68 | 2022 | |
| Cordis US Corp. | $19.49 | 2025 | Mynx Control Venous |
| Tactile Systems Technology INC | $17.97 | 2025 | Nimbl, Flexitouch Plus |
| Lilly USA, LLC | $17.00 | 2025 | Mounjaro, Zepbound |
| Kite Pharma, INC. | $13.49 | 2020 | |
| Medtronic Vascular, INC. | $12.00 | 2019 | |
| Braemar Manufacturing, LLC | $11.86 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Howard Min listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.